<DOC>
	<DOCNO>NCT00567710</DOCNO>
	<brief_summary>This prospective , six-week , randomize , double blind , placebo-controlled , multi-center study patient schizophrenia experience acute exacerbation psychosis .</brief_summary>
	<brief_title>A Six-week , Randomized , Double-blind , Placebo-controlled , Parallel Group , Multi-center , Phase II Study</brief_title>
	<detailed_description>This study consist 5- 14-day screening period include antipsychotic medication washout , follow six-week double blind treatment period . Patients complete 6-week treatment period may continue double-blind treatment optional extension period least 6 week ' duration . Patients randomize placebo initial 6-week period randomize BL-1020 low high dose extension treatment period . Approximately 40 study center four country participate .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patient male female , 1865 year age , inclusive . If female , patient must postmenopausal , fecund , must abstinent practice establish method birth control hormonal preparation ( e.g. , oral contraceptive tablet , hormonal implant device , hormone patch , injectable contraceptive ) , intrauterine device [ IUD ] , least two month prior screen , addition must use barrier method , e.g. , condom , diaphragm , contraceptive foam . Patient willing able provide inform consent , nature study fully explain . Patient inpatient outpatient current DSMIVTR diagnosis schizophrenia , confirm MINIPlus . Patient must experience acute exacerbation psychosis , baseline ( Study Day 0 ) total score PANSS great '70 ' . Patient must score ' 4 ' ( `` moderate '' ) baseline two follow four PANSS item : delusion , hallucinatory behavior , conceptual disorganization suspiciousness/persecution , least one two item must either delusion hallucinatory behavior , total score four item must great '17 ' . Patient must experience acute exacerbation psychosis total score CGIS ' 4 ' ( `` moderate '' ) great baseline . Patient willing hospitalize screening , willing remain hospital least 14 day baseline ( Study Day 14 ) clinically indicate , must willing comply study related evaluation procedure Study Day 42 . Patient caregiver identify responsible person ( e.g. , family member , social worker , nurse ) support him/her ensure compliance treatment outpatient visit . Patient willing comply take prohibited medication participation study . The presence follow exclude patient study enrolment : General Patient unwilling unable provide inform consent . Patient unwilling unable , opinion Investigator , comply study instruction . If female , patient pregnant , breastfeeding , positive urine pregnancy test screen baseline , reproductive capacity unwilling comply accept contraceptive method study , ie , use oral contraceptive , hormonal patch implant , injectable contraceptive IUD , combination barrier method ( see Inclusion Criterion # 2 ) . Patient make plasma blood donation within 14 day prior screen visit . Patient participate prior clinical study BL1020 excipients , and/or receive investigational drug within thirty day prior screen . Patient judge PI inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>